We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02194985
First Posted: July 21, 2014
Last Update Posted: October 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amicus Therapeutics
July 17, 2014
July 21, 2014
October 2, 2017
October 2014
October 2019   (Final data collection date for primary outcome measure)
  • Incidence of adverse events (AEs) [ Time Frame: up to 5 years ]
    non-serious AEs, serious AEs., possible suicidality related AEs
  • Withdrawal due to AEs [ Time Frame: up to 5 years ]
    including non-serious and serious AEs
  • Vital signs and body weight - change in baseline in vital signs and body weight [ Time Frame: up to 5 years ]
    blood pressure and heart rate
  • Change from baseline in laboratory parameters [ Time Frame: up to 5 years ]
    hematology, chemistry, and urinalysis
  • Change from baseline in electrocardiogram (ECG) [ Time Frame: up to 5 years ]
    12-lead ECG
  • Change from baseline in echocardiography [ Time Frame: up to 5 years ]
    echocardiography ultrasound
  • Incidence of adverse events (AEs) [ Time Frame: up to 5 years ]
    non-serious AEs, serious AEs, possible suicidality related AEs
  • Withdrawal due to AEs [ Time Frame: up to 5 years ]
    including non-serious and serious AEs
  • Vital signs and body weight - change in baseline in vital signs and body weight [ Time Frame: up to 5 years ]
    blood pressure and heart rate
  • Change from baseline in laboratory parameters [ Time Frame: up to 5 years ]
    hematology, chemistry, and urinalysis
  • Change from baseline in electrocardiogram (ECG) [ Time Frame: up to 5 years ]
    12-lead ECG
  • Change from baseline in echocardiography [ Time Frame: up to 5 years ]
    echocardiography ultrasound
Complete list of historical versions of study NCT02194985 on ClinicalTrials.gov Archive Site
  • Estimated glomerular filtration rate (eGFR) [ Time Frame: up to 5 years ]
    based on the Modification of Diet in Renal Disease (MDRD) equation and CKD-EPI equation
  • Measurement of left ventricular mass (LVM) and left ventricular mass index (LVMi) [ Time Frame: up to 5 years ]
    as measured by echocardiography
  • Ejection fraction [ Time Frame: up to 5 years ]
    as measured by echocardiography
  • Fractional shortening [ Time Frame: up to 5 years ]
    as assessed by echocardiography
  • Measurement of LV internal dimension (LVIDd and LVIDs) and wall thickness [ Time Frame: up to 5 years ]
    as assessed by echocardiography
  • Measurement of white blood cell (WBC) α-Gal A activity [ Time Frame: up to 5 years ]
    enzyme responsible for breaking down GL-3
  • Measurement of subject reported Quality of Life [ Time Frame: up to 5 years ]
    as assessed by the Short Form - 36 Survey (SF-36)
  • Measurement of 24-hour urine protein [ Time Frame: up to 5 years ]
  • Plasma lyso-Gb3 [ Time Frame: up to 5 years ]
    biomarker shown to be elevated in Fabry subjects
  • Estimated glomerular filtration rate (eGFR) [ Time Frame: up to 5 years ]
    based on the Modification of Diet in Renal Disease (MDRD) equation
  • Evaluation of left ventricular mass index (LVMi) [ Time Frame: up to 5 years ]
    as measured by echocardiography
  • Ejection fraction [ Time Frame: up to 5 years ]
    as measured by echocardiography
  • Fractional shortening [ Time Frame: up to 5 years ]
    as assessed by echocardiography
  • Measurement of LV internal dimension (LVIDd and LVIDs) and wall thickness [ Time Frame: up to 5 years ]
    as assessed by echocardiography
  • Evaluation of white blood cell (WBC) α-Gal A activity [ Time Frame: up to 5 years ]
    enzyme responsible for breaking down GL-3
  • Evaluation of subject reported Quality of Life [ Time Frame: up to 5 years ]
    as assessed by the Short Form - 36 Survey (SF-36)
  • Measurement of 24-hour urine protein [ Time Frame: up to 5 years ]
Not Provided
Not Provided
 
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

This is an open-label extension study intended to provide continued treatment with migalastat HCl for subjects with Fabry disease who completed treatment of a previous migalastat HCl monotherapy study.

The study will assess the long-term safety and effectiveness of migalastat HCl in subjects with Fabry disease who completed migalastat HCl treatment in a previous study.

Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Fabry Disease
Drug: migalastat HCl 150 mg
Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.
Other Name: AT1001
Experimental: migalastat HCl 150 mg
Migalastat HCl is a capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on days between migalastat HCl.
Intervention: Drug: migalastat HCl 150 mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
76
October 2019
October 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject had completed treatment in a previous study of migalastat HCl
  • Age 18 years or older
  • Male and female participant agrees to use protocol identified acceptable contraception
  • Subject is willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI)

Exclusion Criteria:

  • Subjects last available estimated glomerular filtration rate (eGFR) in the previous study was <30 mL/min/1.73m2; unless there is measured GFR available within 3 months of Baseline Visit (Visit 1), which is >30 mL/min/1.73m2
  • Subject has undergone, or is scheduled to undergo kidney transplantation or is currently on dialysis
  • Subject has a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Visit 1
  • Subject has clinically significant unstable cardiac disease in the opinion of the investigator (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)
  • Subject has a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (e.g., miglustat, miglitol)
  • Subject requires treatment with Glyset® (miglitol) or Zavesca® (miglustat)
  • Subjects with severe or unsuitable concomitant medical condition
  • Subjects with clinically significant abnormal laboratory value(s) and clinically significant electrocardiogram (ECG) findings at baseline
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Denmark,   Egypt,   France,   Italy,   Japan,   Spain,   Turkey,   United Kingdom,   United States
 
 
NCT02194985
AT1001-042
Yes
Not Provided
Not Provided
Amicus Therapeutics
Amicus Therapeutics
Not Provided
Study Director: Medical Monitor, Clinical Research, MD Amicus Therapeutics, Inc.
Amicus Therapeutics
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP